Competition Law360 provides breaking news and analysis on antitrust law. Coverage includes high-stakes antitrust litigation and government enforcement actions, as well as legislative and regulatory developments.

Sign up for a 7-day FREE trial today!

Latest News in Competition

• February 13, 2026

  UK Opens Probe Into Daily Mail Owner's £500M Telegraph Deal

  Britain's competition and communications regulators said Friday that they have launched parallel investigations into the proposed £500 million ($680 million) acquisition of Telegraph Media Group by the owner of the Daily Mail newspaper as they respond to instructions from the government.

• February 12, 2026

  FTC Merger Filing Overhaul Thrown Out

  The Federal Trade Commission hasn't shown the costs on merging companies outweigh the claimed benefits of dramatically increasing the amount of information that must be provided upfront when giving notice of a transaction, a Texas federal judge said Thursday, throwing out the commission's overhaul of premerger reporting requirements.

• February 12, 2026

  5 Key Flashpoints From Fed's 'Skinny' Account Proposal

  The Federal Reserve's push to create "skinny" master accounts that would open up access to U.S. payment rails has become the latest front in long-running turf wars between banks and fintech companies. Here are five of the project's hottest flashpoints attracting controversy.

• February 12, 2026

  HPE Has 'No Grounds' To Hide DOJ Deal Bidders, AGs Say

  Democratic attorneys general challenging the controversial Justice Department settlement permitting Hewlett Packard Enterprise's $14 billion purchase of Juniper Networks have urged a California federal judge to let them see who's bidding for assets up for divestiture, arguing the would-be buyers are an integral part of the agreement's viability.

• February 12, 2026

  FTC's PBM Case Paused For More Deal Talks

  Federal Trade Commission staffers are discussing potential settlements with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, following a recent deal with Express Scripts.

See more Competition news